As complex drugs see little competition, the FDA will distribute guidelines to increase approvals of generic medicines for ‘economic stability’ and to bring affordable drugs to patients.
Certara has acquired BaseCase Management GmbH, a data visualization company that helps sponsors communicate health economic evidence and product differentiation information.
Recipham has agreed to pay the founders of Nitin Lifescience Limited INR2.8bn ($44m) for the remaining 26% stake they own in the India-based drug manufacturer.
Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
Evotec AG has acquired Aptuit for $300m as CRO consolidation continues – bringing innovative products forward faster and at a lower cost, says CEO.
Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.
AMRI has received a 5-year federal contract award from the National Institutes of Health (NIH) under which it will provide drug substance development and manufacturing services.
The cost of outsourcing is far more than simply the price per kilogram of an API says Hovione, which is expanding a plant in New Jersey.
Swedish CMO Recipharm has teamed up with formulations and solid state chemistry firm Adroit Science in a strategic collaboration.
Covance has acquired Medaxial, a communications firm specialising in market access strategy and economic modelling.
Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics (DDA) to integrate health economics and outcomes research, predictive modeling and definitive analysis to maximize return on investment for pharmaceutical...
Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.
Investment in Almac’s Northern Ireland plant will keep production costs competitive with low-cost economies, according to the company.
DISPATCHES FROM INTERPHEX
At this year’s Interphex, Kemwell Biopharma spoke to Outsourcing-Pharma.com about recent expansions in both India and the US.
Third-party manufacturers of biologics are seeing increased demand but more short term contracts, according to Fujifilm.
Albemarle is adding new capacity at its manufacturing facility in Pennsylvania with a $30 million expansion.
Icon buys PriceSpective to add pricing skills to outcomes biz
Icon has bought PriceSpective to add market access and pricing capabilities to its growing health outcomes business.
Cobra buys Unitech for capacity boost
Recently independent CMO Cobra Biologics has bought Swedish contract biomanufacturing group Unitech Pharma Group.
West-Ward wants CMO market share after Baxter buy
West-Ward is working to win contract manufacturing market share and tackle drug shortages after buying assets from Baxter.
US drives contract packaging growth at United Drug
Contract packaging profit at United Drug rose in its latest results as strong US sales offset weak performance in Europe.
Pii adds trial scale HME capacity
Pharmaceutics International (Pii) has expanded its range of formulation and process development services with the addition of bioavailability boosting hot-melt extrusion (HME) capabilities.
Icon buys Oxford Outcomes to boost Ph IV biz
Dublin, Ireland-based contract research organisation (CRO) Icon has bought Oxford Outcomes, expanding its late Phase research business.
Materials advances driving autoinjector market, report
Advances in materials technology are driving the autoinjection drug delivery device market according to new research.
West to close US plant and downsize UK site
West Pharmaceutical Services will close a plant in Pennsylvania, US and sell part of a factory Cornwall in the UK to reorganise production operations ahead of impending contract expiries.
Pfizer and IPHA welcome Irish commitment to 12.5 corporation tax rate
Pfizer has welcomed Government commitments to keep Ireland’s 12.5 per cent corporation tax rate in face of recent EU pressure to increase it as a condition of the €85bn 7-year IMF bailout.
RecipharmCobra’s French customers to get tax breaks
RecipharmCobra Biologics has called for more R&D tax breaks in Europe after French Ministry of Higher Education and Research recognises it as key provider.
DSM: XD scale-up can cut drug production costs
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
Covance to close Kalamazoo unit
US CRO Covance will close its testing facility in Kalamazoo, Michigan by the end of November with the loss of 63 jobs.
Hyde opens European office
Hyde Engineering + Consulting has opened an office in Dublin, Ireland, enhancing its ability to provide Europe-based biopharm with compliance, qualification and automation services.
There are signs that 2010 will be a better year for the fine and custom chemistry industry but companies at Informex remained cautious and are planning accordingly.
UK aims to improve manufacturing efficiency
A consortium including GlaxoSmithKline and GEA has been formed to push continuous processing and improve pharma manufacturing efficiency in the UK in response to competition from emerging markets.
Lonza cuts 2009 guidance 14% and plans workforce cuts
Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”
As CPhI 2009 draws to a close we take a look back on the show, which, despite some negatives, appears to have been an overall success.
Reliance on external partners threatens innovation; experts
Pharma’s reliance on outsourcing and products developed by biotechs could cause the pace of innovation to “decline considerably”, according to experts that are concerned about the lack of funding for small businesses.
India’s formulation market worth $14bn by 2013, says Angel Broking
India’s drug formulation market will grow 12 per cent a year and be worth $13.7bn (€9.3bn) by 2013, according to new research by market analysts Angel Broking.
MDS trying to sell Pharma Services business
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
SupplyScape acquired by TraceLink
TraceLink has acquired SupplyScape, a provider of products and services to secure the supply chain, and plans to improve its track and trace offering.
AMRI op income down 97% in Q2
AMRI’s adjusted income from operations plummeted by 97 per cent in Q2 as a result of lower demand for contract services, in particular development and small scale manufacture.
IMS Health to shed 850 jobs
Industry analyst IMS Health will cut 850 jobs over the next 12 to 15 months, including 170 positions at its US operations.
NJ pharma employment down in ‘08
The number of pharma employees in New Jersey, US fell by 1,400 in 2008, with R&D expenditure, capital investment and product trials also declining, according to a report.
Synthetech profits rise but uncertainty lies ahead
Synthetech posted a $1.3m (€0.9m) operating profit in fiscal 2009, compared with a $1.1m (€770,000) loss the previous year, but warned that some biotechs and even major pharmas were cutting back.
Neuland posts big growth despite downturn
Neuland has posted a 35 per cent growth in operating profits in its 2008 financial year, despite the pricing pressures and economic environment that have affected the industry.
Winpak’s Q1 profits soar despite falling sales
Winpak appears to have benefited from the current economic turmoil, with lower raw material costs and favourable currency rates helping it post net earnings of $9.7m (€7.4m), up by 62 per cent on 2008.
Patheon forms alliance with India’s Kemwell
Patheon and India’s Kemwell have formed an alliance under which they will refer and market each others' services to development and manufacturing clients
Asian pack machine demand a boon US and EU industry
The market for packaging machinery is set to grow 5 per cent a year and be worth $40bn (€30.3bn) by 2012, driven partly by a hike in demand for drug products in “pharmerging” economies, according to a new industry report.
Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
Specialists turn to R&D in tough economic times
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Marksans sets sights on EU generics sector
Contract services firm Marksans Pharmaceutical says that the RPS 1bn (€15.4m) acquisition of UK generics group Relonchem will expand its distribution network and build its presence in the European market.
Bosch opens India packaging plant to boost sales, sourcing
Bosch Packaging has opened a new manufacturing facility in Goa, India, to cater to its growing customer base in the booming emerging market and increase sourcing for its European headquarters.